Joseph Pantginis, an analyst from H.C. Wainwright, reiterated the Buy rating on Neuphoria Therapeutics. The associated price target is $21.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Joseph Pantginis has given his Buy rating due to a combination of factors surrounding Neuphoria Therapeutics’s BNC210 program. The upcoming Phase 3 AFFIRM-1 trial is seen as a pivotal moment for the company, building on the success of the Phase 2 PREVAIL trial which demonstrated promising efficacy and a strong safety profile. The AFFIRM-1 trial aims to provide statistically robust data to support regulatory discussions and validate BNC210’s unique mechanism of action, potentially opening doors for business development opportunities.
Key expectations for the AFFIRM-1 trial include a larger sample size and increased statistical power compared to the previous trial, which should confirm and extend the positive signals observed earlier. Additionally, BNC210 has shown a favorable safety profile, differentiating it from other treatments like benzodiazepines, which have significant side effects. The trial’s primary endpoint, based on the Subjective Units of Distress Scale (SUDS), has been validated as a reliable measure of acute anxiety, further solidifying confidence in the trial’s design and potential outcomes.
Pantginis covers the Healthcare sector, focusing on stocks such as Krystal Biotech, Capricor Therapeutics, and Viking Therapeutics. According to TipRanks, Pantginis has an average return of -7.9% and a 39.80% success rate on recommended stocks.